Patents by Inventor Alessandra Bartolozzi

Alessandra Bartolozzi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused Imidazole Derivatives as AHR Antagonists
    Publication number: 20230331705
    Abstract: The present disclosure relates to compounds of formulae (I)-(VI) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling.
    Type: Application
    Filed: May 19, 2021
    Publication date: October 19, 2023
    Inventors: Alessandra Bartolozzi, John Robert Proudfoot, Timothy Briggs, John Mancuso, Maxence Bos, Vu Linh Ly, Anna Blois, Bernard Lanter, Steven John Taylor, Leonard Buckbinder
  • PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS
    Publication number: 20230295152
    Abstract: The present disclosure relates to compounds of formula (Ia) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling. These compounds may also be useful in treating cancer when administered in combination with at least one additional therapy.
    Type: Application
    Filed: November 20, 2020
    Publication date: September 21, 2023
    Applicant: SENDA BIOSCIENCES, INC.
    Inventors: Alessandra BARTOLOZZI, John Robert PROUDFOOT, Timothy BRIGGS, John MANCUSO, Karunakar Reddy BONEPALLY, Patrick BUREAU, Tianlin GUO, Maxence BOS, Anna BLOIS, Bernard LANTER, Steven John TAYLOR, Leonard BUCKBINDER, Francesca BARONE
  • Fused Azole Heterocycles as AHR Antagonists
    Publication number: 20230234967
    Abstract: The present disclosure relates to thiazolo-pyridine, oxazolo-pyridine, pyrrolo-pyridine, pyrrolo-pyrazine and pyrrolo-pyrimidine compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling.
    Type: Application
    Filed: May 27, 2021
    Publication date: July 27, 2023
    Inventors: Alessandra Bartolozzi, John Robert Proudfoot, Timothy Briggs, John Mancuso, Maxence Bos, Tianlin Guo, Vu Linh Ly, Anna Blois, Bernard Lanter, Steven John Taylor, Leonard Buckbinder
  • INHIBITORS OF MICROBIALLY INDUCED AMYLOID
    Publication number: 20230113225
    Abstract: The present disclosure provides compounds useful for the prevention of amyloid formation and the treatment of amyloid related disorders, including synucleopathics such as Parkinson's Disease.
    Type: Application
    Filed: August 4, 2022
    Publication date: April 13, 2023
    Applicant: Axial Therapeutics, Inc.
    Inventors: Anthony Stewart Campbell, Bridget Cole, Alessandra Bartolozzi
  • INHIBITORS OF MICROBIALLY INDUCED AMYLOID
    Publication number: 20230103887
    Abstract: The present disclosure provides compounds useful for the prevention of amyloid formation and the treatment of amyloid related disorders, including synucleopathies such as Parkinson's Disease.
    Type: Application
    Filed: August 4, 2022
    Publication date: April 6, 2023
    Applicant: Axial Therapeutics, Inc.
    Inventors: Anthony Stewart Campbell, Bridget Cole, Alessandra Bartolozzi
  • Inhibitors of microbially induced amyloid
    Patent number: 11505528
    Abstract: The present disclosure provides compounds useful for the prevention of amyloid formation and the treatment of amyloid related disorders, including synucleopathies such as Parkinson's Disease.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: November 22, 2022
    Assignee: Axial Therapeutics, Inc.
    Inventors: Anthony Stewart Campbell, Bridget Cole, Alessandra Bartolozzi
  • PHARMACOKINETICALLY IMPROVED COMPOUNDS
    Publication number: 20210017166
    Abstract: The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and or ROCK2 that are useful for the treatment of disease.
    Type: Application
    Filed: February 24, 2020
    Publication date: January 21, 2021
    Inventors: Alessandra Bartolozzi, Stewart Campbell, Hope Foudoulakis, Brian Kirk, Siya Ram, Paul Sweetnam, Hemalatha Seshadri
  • INHIBITORS OF MICROBIALLY INDUCED AMYLOID
    Publication number: 20200290970
    Abstract: The present disclosure provides compounds useful for the prevention of amyloid formation and the treatment of amyloid related disorders, including synucleopathies such as Parkinson's Disease.
    Type: Application
    Filed: August 6, 2018
    Publication date: September 17, 2020
    Applicant: Axial Biotherapeutics, Inc.
    Inventors: Anthony Stewart Campbell, Bridget Cole, Alessandra Bartolozzi
  • Pharmacokinetically improved compounds
    Patent number: 10570123
    Abstract: The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and or ROCK2 that are useful for the treatment of disease.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: February 25, 2020
    Assignee: SURFACE LOGIX, LLC
    Inventors: Alessandra Bartolozzi, Stewart Campbell, Hope Foudoulakis, Brian Kirk, Siya Ram, Paul Sweetnam, Hemalatha Seshadri
  • PHARMACOKINETICALLY IMPROVED COMPOUNDS
    Publication number: 20190177311
    Abstract: The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and or ROCK2 that are useful for the treatment of disease.
    Type: Application
    Filed: July 19, 2018
    Publication date: June 13, 2019
    Inventors: Alessandra Bartolozzi, Stewart Campbell, Hope Foudoulakis, Brian Kirk, Siya Ram, Paul Sweetnam, Hemalatha Seshardri
  • PHARMACOKINETICALLY IMPROVED COMPOUNDS
    Publication number: 20180072710
    Abstract: The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and or ROCK2 that are useful for the treatment of disease.
    Type: Application
    Filed: April 24, 2017
    Publication date: March 15, 2018
    Inventors: Alessandra Bartolozzi, Stewart Campbell, Hope Foudoulakis, Brian Kirk, Siya Ram, Paul Sweetnam, Hemalatha Seshardri
  • Inhibitors of microsomal triglyceride transfer protein and apo-B secretion
    Patent number: 9656960
    Abstract: The present invention relates to compounds which are inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion. These compounds can be useful for the prevention and treatment of various diseases, particularly atherosclerosis and its clinical sequelae, for lowering serum lipids, and related ailments. The invention further relates to pharmaceutical compositions comprising the compounds and to methods of treating diseases, such as hypertriglyceridemia, hyperchylomicronemia, atherosclerosis, obesity, and related conditions using the compounds. A method for decreasing apolipoprotein B (apo B) secretion is also provided.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: May 23, 2017
    Assignee: Surface Logix, Inc.
    Inventors: Alessandra Bartolozzi, Stewart Campbell, Hope Foudoulakis, Enoch Kim, Paul Sweetnam, Yingfei Yang
  • Rho-kinase inhibitors and method of preparation
    Patent number: 9440961
    Abstract: The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and or ROCK2 that are useful for the treatment of disease.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: September 13, 2016
    Assignee: SURFACE LOGIX, INC.
    Inventors: Alessandra Bartolozzi, Stewart Campbell, Hope Foudoulakis, Brian Kirk, Siya Ram, Paul Sweetnam, Hemalatha Seshadri
  • Compounds which modulate the CB2 receptor
    Patent number: 9315454
    Abstract: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: April 19, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Alessandra Bartolozzi, Angela Berry, Doris Riether, Monika Ermann, James Edward Jenkins, Innocent Mushi
  • INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND APO-B SECRETION
    Publication number: 20160039765
    Abstract: The present invention relates to compounds which are inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion. These compounds can be useful for the prevention and treatment of various diseases, particularly atherosclerosis and its clinical sequelae, for lowering serum lipids, and related ailments. The invention further relates to pharmaceutical compositions comprising the compounds and to methods of treating diseases, such as hypertriglyceridemia, hyperchylomicronemia, atherosclerosis, obesity, and related conditions using the compounds. A method for decreasing apolipoprotein B (apo B) secretion is also provided.
    Type: Application
    Filed: March 17, 2015
    Publication date: February 11, 2016
    Inventors: Alessandra Bartolozzi, Stewart Campbell, Hope Foudoulakis, Enoch Kim, Paul Sweetnam, Yingfei Yang
  • PHARMACOKINETICALLY IMPROVED COMPOUNDS
    Publication number: 20150344464
    Abstract: The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and or ROCK2 that are useful for the treatment of disease.
    Type: Application
    Filed: December 23, 2014
    Publication date: December 3, 2015
    Inventors: ALESSANDRA BARTOLOZZI, STEWART CAMPBELL, HOPE FOUDOULAKIS, BRIAN KIRK, SIYA RAM, PAUL SWEETNAM
  • Heterocyclic compounds as inhibitors of leukotriene production
    Patent number: 9174980
    Abstract: The present invention relates to compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R1-R7, A and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: November 3, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Alessandra Bartolozzi, Zhidong Chen, Jonathon Alan Dines, Ho Yin Lo, Pui Leng Loke, Alan Olague, Doris Riether, Heather Tye, Lifen Wu, Renee M. Zindell
  • Inhibitors of microsomal triglyceride transfer protein and apo-B secretion
    Patent number: 8980915
    Abstract: The present invention relates to compounds which are inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion. These compounds can be useful for the prevention and treatment of various diseases, particularly atherosclerosis and its clinical sequelae, for lowering serum lipids, and related ailments. The invention further relates to pharmaceutical compositions comprising the compounds and to methods of treating diseases, such as hypertriglyceridemia, hyperchylomicronemia, atherosclerosis, obesity, and related conditions using the compounds. A method for decreasing apolipoprotein B (apo B) secretion is also provided.
    Type: Grant
    Filed: April 19, 2006
    Date of Patent: March 17, 2015
    Assignee: Surface Logix, Inc.
    Inventors: Alessandra Bartolozzi, Stewart Campbell, Hope Foudoulakis, Enoch Kim, Paul Sweetnam, Yingfei Yang
  • Pharmacokinetically improved compounds
    Patent number: 8916576
    Abstract: The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and or ROCK2 that are useful for the treatment of disease.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: December 23, 2014
    Assignee: Surface Logix, Inc.
    Inventors: Alessandra Bartolozzi, Stewart Campbell, Hope Foudoulakis, Brian Kirk, Siya Ram, Paul Sweetnam, Hemalatha Seshadri
  • Heterocyclic compounds which modulate the CB2 receptor
    Patent number: 8889670
    Abstract: Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
    Type: Grant
    Filed: February 16, 2010
    Date of Patent: November 18, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Alessandra Bartolozzi, Angela Berry, Pier Francesco Cirillo, Eugene Richard Hickey, Doris Riether, Lifen Wu, Renee M. Zindell